Ivermectin does not speed up recovery time from non-serious COVID

Ivermectin does not speed up recovery time from non-serious COVID

Adding further evidence that the antiparasitic drug ivermectin is ineffective as a treatment for COVID-19, preliminary findings from an ongoing randomized, controlled clinical trial of repurposed drugs today in THE PIT finds that it does not speed up recovery time in patients with mild to moderate infections.

Ivermectin, which is used worldwide to treat human worm infestations and parasitic infections in animals, has been investigated as a drug for COVID-19 after an in vitro study suggested antiviral activity, but evidence of its benefit is lacking.

Three days of treatment or placebo

A team led by the Duke Clinical Research Institute led a remote, double-blind trial of the platform that included 1,591 non-hospitalized COVID-19 patients aged 30 and older who had at least two symptoms for a week or less from June 23, 2021 to 4 February. , 2022, at 93 US locations. Monitoring continued until May 31. The research period included periods of dominance of the Delta and Omicron variants.

Participants were randomly assigned to receive either 400 micrograms per kilogram ivermectin tablets (817 patients) or placebo (774) for 3 days. They completed daily assessment of symptoms and adverse events via the study portal for 14 days, then at variable intervals through day 28 and day 90.

The mean age was 48 years, 58.6% were female, 81% were white, 10% were Hispanic, 7% were black, and 47.3% reported receiving two or more doses of the COVID vaccine -19. The average time from the onset of symptoms to receiving the study drug was 6 days. Chronic conditions were common, including obesity (41%), diabetes (11.5%), high blood pressure (26%), asthma (15%), and chronic obstructive pulmonary disease (4%).

Findings ‘do not support’ ivermectin

The hazard ratio (HR) for faster recovery was 1.07 (95% confidence interval). [CrI], 0.96 to 1.17; posterior probability of benefit, .91), indicating no benefit. The median time to recovery (at least 3 consecutive symptom-free days) was 12 days among ivermectin recipients and 13 days in the placebo group.

Ten participants in the ivermectin group and nine placebo recipients were hospitalized (1.2% each; HR, 1.1), while 3.9% of the former and 3.6% of the latter visited an emergency room or emergency room, were hospitalized, or died. One ivermectin recipient died.

Adverse events were infrequent and similar in the two groups (2.8% of ivermectin recipients vs. 3.5% of the placebo group). The most common serious adverse events were COVID-19 pneumonia (five in the ivermectin group, seven in the placebo group) and venous thromboembolism (blood clot in a vein) (one and five, respectively).

“Among outpatients with mild to moderate COVID-19, treatment with ivermectin, compared with placebo, did not significantly improve time to recovery,” the study authors wrote. “Lack of treatment effect was also observed for secondary clinical outcomes including hospitalization, death, or acute care visits. These findings do not support the use of ivermectin in patients with mild to moderate COVID-19.”

#Ivermectin #speed #recovery #time #nonserious #COVID

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button